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Vascular endothelial growth factor
Microvessel densityABSTRACT
Objective: To observe the antitumor effect and mechanism of recombinant human
endostatin (Endostar) injection in tumor combined with intraperitoneal injection of
cisplatin on subcutaneous transplanted Lewis lung cancer in rats.
Methods: A total of 30 C57 rats were selected, and the monoplast suspension of Lewis
lung cancer was injected into the left axilla to prepare the subcutaneous transplanted
tumor models in the axilla of right upper limb. The models were randomly divided into
Groups A, B, and C. Medication was conducted when the tumor grew to 400 mm3. Group
A was the control group without any interventional treatment. Group B was injected with
Endostar 5 mg kg−1 d−1 for 10 d. Group C was given the injection of Endostar
5 mg kg−1 d−1 combined with intraperitoneal injection of cisplatin 5 mg kg−1 d−1 for 10 d.
All the rats in three groups were executed the day after the 10 d medication and the tumor
was taken off for measurement of volume and mass changes and calculation of antitumor
rate, after which the vascular endothelial growth factor (VEGF) concentration in rats'
plasma was determined by ELISA. The tumor tissues were cut for the preparation of
conventional biopsies. After hematoxylin-eosin staining, the pathologic histology was
examined to observe the structures of tumor tissues, VEGF score and microvessel density
(MVD) in each group.
Results: The volume and mass of tumor in Groups B and C were signiﬁcantly lower
than Group A (P < 0.05) while the tumor volume and mass in Group C were signiﬁ-
cantly lower than Group B (P < 0.05). The antitumor rate in Group C was signiﬁcantly
higher than Group B (P < 0.05), but the tumor VEGF score, MVD and plasma VEGF
level in Group C were signiﬁcantly lower than Groups A and B (P < 0.05). In Group B,
the tumor VEGF score, MVD and plasma VEGF level were signiﬁcantly lower than
Group A (P < 0.05). The microscopic image of Group C showed that its number of
active tumor cells and the blood capillary around tumor was signiﬁcantly smaller than
that of Groups A and B, and meanwhile atrophy and liquefactive necrosis were seen in
local tumor.
Conclusions: Endostar injection combined with intraperitoneal injection of cisplatin is
effective in reducing tumor VEGF score and MVD of transplanted tumor tissues in rats
with Lewis lung cancer to obstruct the nutrient supply of tumor cells and kill tumor cells,
so that the inhibition of tumor cell proliferation and metastasis can be achieved with a
remarkable effect.Cancer Hospital and Institute, Dalian Medical
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Lung cancer is a common malignancy in respiratory system,
ranging the top of incidence of all the malignant cancers [1–3].
According to the pathological characteristics, the lung cancer
can be divided into small cell lung cancer and non-small-cell
lung cancer; according to statistics, non-small-cell lung can-
cer in lung cancer patients accounts for about 75%–85% [4].
The conventional therapy for lung cancer is basically
surgery, radiotherapy and chemotherapy, with toxic side
effects, liability to relapse and metastasize, and low survival
rate of 5 years for patients [5]. Therefore, how to improve the
efﬁciency of non-small-cell lung cancer treatment and reduce
the toxic side effects have been urgent problems in antitumor
research ﬁeld. It has been widely and clinically recognized that
tumor grows depending on angiogenesis and that the tumor
invasion and metastasis are closely connected to angiogenesis
of tumor tissues; hence, anti-angiogenesis has become the
research highlight of oncotherapy [6]. Angiostatin is a new
angiogenesis inhibitor and can play a speciﬁc inhibitory role
in vascular endothelial cells with heparin [5–7]. Researches
conﬁrm that vascular endostatin at normal level has the
particular inhibitory effect in tumor growth [8,9]. In the
present research, the antitumor effect of Endostar injection in
tumor combined with intraperitoneal injection of cisplatin on
subcutaneous transplanted Lewis lung cancer in rats
was observed by taking C57 rats as models of subcutaneous
transplanted Lewis lung cancer ready for the medication.
The antitumor mechanism and effect were observed,
aiming to provide an experimental basis for the clinical
treatment.2. Materials and methods
2.1. Experimental animals
A total of 30 clean C57/6J rats were purchased from
Shanghai Lab, Animal Research Center, with age of 5–7 weeks,
weight of (21 ± 3) g, humidity for raising of (60 ± 5)%, and
temperature at (25 ± 2) C, and food and water were available ad
libitum. The whole experimental process was conducted strictly
sticking to Regulations for the Administration of Affairs Con-
cerning Experimental Animals.2.2. Equipments and reagents
Endostar injection was purchased from Shandong Simcere-
Medgenn Bio-pharmaceutical Co., Ltd., with batch number
20130404 and standard of 15 mg/piece. Cisplatin injection
was provided by Mayne Pharma Pty. Ltd., with batch
number U131881AA and standard of 50 mg/piece. The
monoclonal antibodies of rabbit-anti-rat endothelial cell CD34
antigen and rabbit-anti-rat VEGF antigen were provided by
Beijing Zhongshan Golden Bridge-Biotechnology Co., Ltd.
Phosphate buffered saline (buffer, Strept Avidin–Biotin Com-
plex kit, 3,30-diaminobenzidine color-substrate solution and
related reagents were purchased from Shanghai Senxiong
Biotechnology Co., Ltd. Olympus BH-2 microscope was from
Japan.2.3. Model preparation and group treatments
Well-grown tumors in tumor-bearing rats were taken for the
preparation of monoplast suspension 2 × 106/mL by homoge-
nization. A total of 0.2 mL of the prepared suspension was taken
to inoculate in the subcutaneous tissues of axilla beneath rats'
right upper limb, after which the rats were divided randomly into
Groups A, B, and C, with 10 in each. Medication was performed
when the tumor volume reached 400 mm3. Group A was the
control group without any medication. Group B was given
Endostar 5 mg$kg−1$d−1 injection directly in tumor for contin-
uous 10 d while Group C was given Endostar injection
5 mg$kg−1$d−1 combined with intraperitoneal injection of
cisplatin 5 mg$kg−1$d−1 for continuous 10 d.
2.4. Observation indicators
All the rats were executed the day after the 10 d medication.
The volume and mass of tumor were then measured and the
antitumor rate was calculated. The blood from rats' eyeballs was
taken for the determination of vascular endothelial growth factor
(VEGF) level in plasma by double antibody sandwich ELISA
assay. After the measurement and weighing of tumor, conven-
tional tissue biopsies were prepared. After hematoxylin-eosin
staining was conducted, the necrosis and metastasis of tumor
were observed under light microscope. VEGF and microvessel
density (MVD) of tumor tissue were determined by immuno-
histochemical method.
2.5. Result determination
According to method of Rahman et al., the VEGF expression
was scored and radio of positive cells were scored based on
dyeing range and intensity. Dyeing intensity was ranged 0–3
levels, namely, level 0: negative; level 1: weakly positive; level
2: positive; level 3: strongly positive. Dyeing techniques were
ranged from 0 to 4 levels, namely, level 0: negative; level 1:
positive cells 1%–25%; level 2: positive cells 26%–50%; level
3: positive cells 51%–75%; level 4: positive 76%–100%. The
densest dyeing area of blood vessels of tumor in biopsies at high
magniﬁcation was for the MVD count and 5 random counts
were taken for the average value of microvessel numbers.
2.6. Statistical processing
The data were processed by SPSS 13.0 and measurement
data were expressed by mean ± sd. One-way ANOVA was
performed by pairwise comparison and Q test was conducted. If
P < 0.05, statistical signiﬁcance was considered to exist.
3. Results
3.1. Comparison of tumor volume, mass and antitumor
rates in groups
Both tumor volume and mass in Groups B and C were
signiﬁcantly lower than Group A (P < 0.05). Tumor volume and
mass in Group C were signiﬁcantly lower than Group B
(P < 0.05). The antitumor rate in Group C was signiﬁcantly
higher than Group B (P < 0.05). Speciﬁc results were shown in
Table 1.
Table 2
Comparison of tumor VEGF, MVD and plasma VEGF in groups.
Groups n Tumor Plasma VEGF (pg/mL)
VEGF score MVD
Group A 10 6.4 ± 0.9 13.8 ± 1.9 115.58 ± 19.92
Group B 10 4.4 ± 0.5* 4.4 ± 1.7* 51.90 ± 11.02*
Group C 10 3.4 ± l.1*# 1.8 ± 0.8*# 12.63 ± 3.94*#
Compared with Group A, *P < 0.05; Compared with Group B,
#P < 0.05.
Table 1
Comparison of tumor volume, mass and antitumor rates in groups.
Groups n Volume (mm3) Mass (g) Antitumor
rate (%)
Group A 10 2 470.00 ± 392.47 3.75 ± 0.51 –
Group B 10 1 785.68 ± 256.62* 2.59 ± 0.27* 27.53
Group C 10 707.24 ± 189.88*# 1.00 ± 0.24*# 74.13#
Compared with Group A, *P < 0.05; Compared with Group B,
#P < 0.05.
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VEGF in groups
The tumor VEGF score, MVD and plasma VEGF level in
Group C were signiﬁcantly lower than Groups A and B
(P < 0.05). The tumor VEGF score, MVD and plasma VEGF
level in Group B were signiﬁcantly lower than Groups A
(P < 0.05). Speciﬁc results were shown in Table 2.
3.3. Histological observation
In Group A, there was clear demarcation between tumor and
the surrounding tissues. The tumor was with hilic growth,
complete but easy-to-peel capsule. The cut of tumor was grey
white. The tumor cells grew vigorously and the tumor was
surrounded by abundant blood capillary. In Group B, several
caseous necrosis and large area of focal necrosis were seen in the
central part of tumor. The number of tumor cells and blood
capillary surrounding tumor was obviously smaller than Group
A. In Group C, the active tumor cells were obviously fewer than
Groups A and B. Atrophy and liquefaction necrosis were easily
seen in parts of tumor, and the blood capillary surrounding tu-
mor was the fewest in Group C. Speciﬁc results were shown in
Figure 1.Figure 1. Results of histopathological observation (HE, ×200).4. Discussion
Lung cancer is the common malignant disease in respiratory
system, with increasing incidence in recent years, and has top-
ped the morbidity and mortality of malignancy. At present, the
surgery, radiotherapy and chemotherapy are still the major
therapeutic regimens, but radiotherapy and chemotherapy are of
heavy toxic side effects which are detrimental to the survival rate
of patients [10–13]. The growth and metastasis of malignant
tumor are dependent on the vasifaction of new blood vessels
which can ensure the nutrient supply of tumor cells; hence,
anti-angiogenesis has been the new focus in therapy for malig-
nant tumor [14]. Anti-angiogenesis targeted drugs that are not
prone to show drug resistance and of low toxicity have become
the research focus in tumor therapeutic area. The present
research observed the effect of anti-angiogenesis drug, endo-
statin, combined with cisplatin, on growth and metastasis of
tumor in rats with transplanted Lewis lung cancer and aimed to
provide the experimental basis for clinical treatment.
Experiments have conﬁrmed that angiostatin carries signiﬁcant
inhibitory effect on growth ofmalignant tumors of all kinds and can
reduce the proliferation and metastasis of tumors [15–18]. Other
experiments also conﬁrm that endostatin at normal level can
signiﬁcantly inhibit tumor growth but when it is lower than
normal level, the tumor would grow 2–3 times faster. Many
researchers believe that the process is the result of multiple target
points and multiple steps [19]. Endostar is the new recombinant
human endostatin in recent years, whose functional mechanism is
to inhibit the new tumor angiogenesis by inhibiting the metastasis
of endothelial cells in blood vessels, so that the nutrient supply of
tumor can be blocked and therefore the proliferation and
metastasis of tumor can be inhibited [20]. In-vitro experiment
results showed that Endostar had inhibitory effect in the
metastasis of human microvascular endothelial cells and
formation of tubes, and meanwhile could signiﬁcantly inhibit
angiogenesis of chick chorioallantoic membrane which implied
that Endostar carries in-vitro anti-angiogenesis effect; in addition,
Endostar plays an inhibitory effect in human lung adenocarcinoma
cell SPC-A4 and gastric carcinoma cell SGC7901 [21,22]. cis-
Dichlorodiammineplatinum(II) or DDP is the ﬁrst line
chemotherapy for treatment in kinds of solid tumors, with broad
anticancer spectrum, strong function, no cross-resistance and
other advantages, and it can be used with many antineoplastic
drugs, producing a synergistic effect which makes it the most
common drug in current combined chemotherapy; VP-16 plus EP
regimen is the ﬁrst line therapy for treatment in small cell lung
cancer or non-small-cell lung cancer, with signiﬁcant antitumor
effect [23,24]. The present research treated the ratswith subcutaneous
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combined with intraperitoneal injection of cisplatin. After the
treatment, in Group C, the volume and quality of tumor were
signiﬁcantly lower than Groups A and B (P < 0.05) and the
antitumor rate was signiﬁcantly higher than Group B (P < 0.05),
which showed that Endostar injection in tumor can signiﬁcantly
inhibit the growth and proliferation of tumor, and that injection
combined with intraperitoneal injection of cisplatin can play a
synergetic inhibitory effect with better efﬁcacy than single
medication. The present research showed that tumor VEGF,
MVD and plasma VEGF levels in Group C were signiﬁcantly
lower than Groups A and B (P < 0.05) and tumor VEGF, MVD
and plasma VEGF levels in Group B were signiﬁcantly lower
than Group A (P < 0.05), suggesting that Endostar injection
combined with cisplatin can effectively reduce the tumor VEGF
expression and plasma VEGF level of rats with subcutaneous
transplanted Lewis lung cancer so that the tumor angiogenesis
can be reduced and antitumor goal can be achieved.
Histopathological observation showed that the positive tumor
cells in tumor tissue of rats in Group C were obviously fewer
than Groups A and B, with atrophy and liquefaction necrosis in
parts of tumor and the fewest blood capillary around tumor; that
also conﬁrmed that Endostar can effectively inhibit the tumor
angiogenesis so that the nutrient supply of tumor cells can be
blocked and tumor cell apoptosis can be accelerated.
Furthermore, cisplatin can directly kill tumor cells and cause
atrophy and liquefaction necrosis in tumor tissue. The
combination of two medications makes a better antitumor effect.
The research conﬁrmed that Endostar injection in tumor
combined with intraperitoneal injection of cisplatin can signiﬁ-
cantly inhibit the VEGF and MVD of rats with subcutaneous
transplanted Lewis lung cancer so that the nutrient supply of
tumor cells can be blocked and tumor cells can be killed directly,
so the proliferation and metastasis of tumor cells can be inhibited.Conﬂict of interest statement
We declare that we have no conﬂict of interest.
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